AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7263143 — intervention group
Group type: EXPERIMENTAL
Intervention: CogentinTM (benztropine mesylate) at increasing doses (maximum 2 mg)
Number of subjects: 29
Study 7263143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30989965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Anshen Fang (Traditional Chinese Medicine)
Number of subjects: 67
Study 30989965 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67
Study 28980140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) and paracetamol (1000 mg)
Number of subjects: 226
Study 28980140 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (10 mg) alone
Number of subjects: 226
Study 26476354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra mini percutaneous nephrolithotomy
Number of subjects: 94
Study 25041377 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 105
Study 25041377 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-EU
Number of subjects: 105
Study 25041377 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-US
Number of subjects: 105
Study 22021080 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma peptides (gp100, MART-1, tyrosinase) with GM-CSF, IFN-α2b or both
Number of subjects: 37
Study 22021080 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF and/or IFN-α2b
Number of subjects: 37
Study 22021080 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) tet(+) T cells
Number of subjects: 37
Study 22021080 — intervention group
Group type: COMPARATOR
Intervention: IFN-γ ELISPOT assays
Number of subjects: 37
Study 19352588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim 2 microg/kg per day for 4 weeks (Step 1)
Number of subjects: 11
Study 19352588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim 6 microg/kg per day for 4 weeks (Step 2)
Number of subjects: 11
Study 19352588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim 6 microg/kg per day (Step 2)
Number of subjects: 11
Study 17234505 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triacylglycerols (LCTs)
Number of subjects: 9
Study 17234505 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain and long-chain triacylglycerols (MCTs/LCTs)
Number of subjects: 9
Study 15222836 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years program
Number of subjects: 373
Study 15222836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 373
Study 15222836 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 373
Study 12202439 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 122
Study 12202439 — intervention group
Group type: COMPARATOR
Intervention: Surgical evacuation
Number of subjects: 122
Study 9718903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD)
Number of subjects: 28
Study 9718903 — intervention group
Group type: COMPARATOR
Intervention: Control group (CSS)
Number of subjects: 28
Study 9718903 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD with defective GH secretion
Number of subjects: 28
Study 9718903 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD
Number of subjects: 28
Study 8624428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF) treated spermatozoa
Number of subjects: 49
Study 8624428 — intervention group
Group type: COMPARATOR
Intervention: Control spermatozoa
Number of subjects: 49
Study 8624428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF) treated embryos
Number of subjects: 49
Study 8624428 — intervention group
Group type: COMPARATOR
Intervention: Control embryos
Number of subjects: 49
Study 8624428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PF and control embryos
Number of subjects: 49
Study 8624428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF)
Number of subjects: 49
Study 2750998 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (1 g, intravenous)
Number of subjects: 23
Study 2750998 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 23
Study 993455 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who believed they had consumed an alcoholic beverage
Number of subjects: 40
Study 993455 — intervention group
Group type: COMPARATOR
Intervention: Subjects who believed they had consumed a nonalcoholic beverage
Number of subjects: 40
Study 31692244 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 269
Study 31692244 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 269
Study 31692244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 28586771 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bag manual morcellation (experimental group)
Number of subjects: 72
Study 28586771 — intervention group
Group type: COMPARATOR
Intervention: Uncontained power morcellation (control group)
Number of subjects: 72
Study 28586771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (in-bag manual morcellation and uncontained power morcellation)
Number of subjects: 72
Study 27524909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clove-based herbal mouthwash
Number of subjects: 14
Study 24172719 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 11
Study 24172719 — intervention group
Group type: COMPARATOR
Intervention: Cola matched for caffeine and CHO (CC)
Number of subjects: 11
Study 24172719 — intervention group
Group type: COMPARATOR
Intervention: Flavored placebo (PL)
Number of subjects: 11
Study 22233243 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Number of subjects: 59
Study 22233243 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 59
Study 19446864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg with 400 mg phytosterols
Number of subjects: 0
Study 19446864 — intervention group
Group type: COMPARATOR
Intervention: Non-enteric coated aspirin 81 mg
Number of subjects: 0
Study 18382886 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 50
Study 18382886 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor therapy
Number of subjects: 50
Study 15704148 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive journal writing
Number of subjects: 43
Study 12906958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands
Number of subjects: 739
Study 12906958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustimulation band
Number of subjects: 739
Study 12906958 — intervention group
Group type: COMPARATOR
Intervention: No band control condition
Number of subjects: 739
Study 10338176 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 105
Study 10338176 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine
Number of subjects: 105
Study 10338176 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study 8609071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative transcatheter arterial embolization (TAE)
Number of subjects: 97
Study 8609071 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative transcatheter arterial embolization (TAE)
Number of subjects: 97
Study 1938514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose total body irradiation (TBI)
Number of subjects: 93
Study 1938514 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (CHVmP)
Number of subjects: 93
Study 6110090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 rad craniospinal radiation therapy (RT)
Number of subjects: 478
Study 6110090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 rad cranial RT plus intrathecal methotrexate (i.t. MTX)
Number of subjects: 478
Study 6110090 — intervention group
Group type: COMPARATOR
Intervention: 1800 rad craniospinal radiation therapy (RT)
Number of subjects: 478
Study 6110090 — intervention group
Group type: COMPARATOR
Intervention: 1800 rad cranial RT plus intrathecal methotrexate (i.t. MTX)
Number of subjects: 478
Study 31523425 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich ready-made meals and dairy products
Number of subjects: 98
Study 31523425 — intervention group
Group type: COMPARATOR
Intervention: Lower protein products
Number of subjects: 98
Study 29089169 — intervention group
Group type: COMPARATOR
Intervention: naproxen + placebo
Number of subjects: 240
Study 29089169 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen + orphenadrine
Number of subjects: 240
Study 29089169 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen + methocarbamol
Number of subjects: 240
Study 29089169 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 240
Study 29089169 — intervention group
Group type: EXPERIMENTAL
Intervention: orphenadrine
Number of subjects: 240
Study 29089169 — intervention group
Group type: EXPERIMENTAL
Intervention: methocarbamol
Number of subjects: 240
Study 26930603 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg)
Number of subjects: 14
Study 26930603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 24997137 — intervention group
Group type: EXPERIMENTAL
Intervention: CbEOb (carboplatin/etoposide with obatoclax)
Number of subjects: 155
Study 24997137 — intervention group
Group type: COMPARATOR
Intervention: CbE (carboplatin/etoposide without obatoclax)
Number of subjects: 155
Study 24997137 — intervention group
Group type: EXPERIMENTAL
Intervention: CbEOb
Number of subjects: 155
Study 24997137 — intervention group
Group type: COMPARATOR
Intervention: CbE
Number of subjects: 155
Study 24997137 — intervention group
Group type: EXPERIMENTAL
Intervention: CbEOb and CbE
Number of subjects: 155
Study 23161047 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005% (LP)
Number of subjects: 199
Study 23161047 — intervention group
Group type: COMPARATOR
Intervention: No intervention (normals)
Number of subjects: 199
Study 23161047 — intervention group
Group type: COMPARATOR
Intervention: No intervention (patients with OH)
Number of subjects: 199
Study 23161047 — intervention group
Group type: COMPARATOR
Intervention: No intervention (patients with POAG)
Number of subjects: 199
Study 20736443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17802
Study 20736443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 18842999 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavones (84 mg/d)
Number of subjects: 34
Study 18842999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16093744 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive childhood abuse history (women)
Number of subjects: 110
Study 16093744 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive childhood abuse history (both genders)
Number of subjects: 110
Study 16093744 — intervention group
Group type: COMPARATOR
Intervention: No childhood abuse history (women)
Number of subjects: 110
Study 16093744 — intervention group
Group type: COMPARATOR
Intervention: No childhood abuse history (both genders)
Number of subjects: 110
Study 12613016 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (3M)
Number of subjects: 103
Study 12613016 — intervention group
Group type: COMPARATOR
Intervention: TAP-144-SR (1M)
Number of subjects: 103
Study 11134564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose platelet transfusions (38% reduction in mean platelet dose)
Number of subjects: 0
Study 9094889 — intervention group
Group type: EXPERIMENTAL
Intervention: 60%‐carbohydrate diet
Number of subjects: 10
Study 9094889 — intervention group
Group type: COMPARATOR
Intervention: 40%‐carbohydrate diet
Number of subjects: 10
Study 1488937 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (.75 ml/kg)
Number of subjects: 130
Study 1488937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (.33 ml/kg)
Number of subjects: 130
Study 1488937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 1488937 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (uncontrollable aversive noise)
Number of subjects: 130
Study 3099267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, within 2 to 4 hours of delivery (Group A)
Number of subjects: 150
Study 3099267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, on days 1 and 8 (Group B)
Number of subjects: 150
Study 3099267 — intervention group
Group type: COMPARATOR
Intervention: Control group received no immunoglobulin (Group C)
Number of subjects: 150
Study 29341077 — intervention group
Group type: EXPERIMENTAL
Intervention: ESU model with enhanced user interface design principles
Number of subjects: 36
Study 29341077 — intervention group
Group type: COMPARATOR
Intervention: Standard ESU model
Number of subjects: 36
Study 27150393 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose intravenous infusion
Number of subjects: 10
Study 27150393 — intervention group
Group type: COMPARATOR
Intervention: Normal saline intravenous infusion (control)
Number of subjects: 10
Study 25663170 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa carbidopa 100 mg
Number of subjects: 10
Study 25663170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 1.5 mg (150 mg LED)
Number of subjects: 10
Study 25663170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23921089 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable staples
Number of subjects: 100
Study 23921089 — intervention group
Group type: COMPARATOR
Intervention: Metallic staples
Number of subjects: 100
Study 21619921 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG-body (3g)
Number of subjects: 13
Study 21619921 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG-rootlets (3g)
Number of subjects: 13
Study 21619921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17960793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcitriol (DN-101; 45 mug) plus docetaxel (36 mg/m2)
Number of subjects: 250
Study 17960793 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (36 mg/m2)
Number of subjects: 250
Study 16504428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous combined hormone therapy (conjugated equine oestrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d or 5 mg/d)
Number of subjects: 1778
Study 14583107 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard advanced cardiac life support (ACLS) intervention and empiric early administration of bicarbonate
Number of subjects: 874
Study 14583107 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 874
Study 14583107 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable outcome risk for men
Number of subjects: 874
Study 14583107 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HTN) prevalence
Number of subjects: 874
Study 10892762 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65 T-cell response in SMS patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: COMPARATOR
Intervention: GAD65 T-cell response in T1DM patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65 fragment response in SMS patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: COMPARATOR
Intervention: GAD65 fragment response in T1DM patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD antibodies in SMS patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: COMPARATOR
Intervention: GAD antibodies in T1DM patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG1 isotype in SMS and T1DM patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: EXPERIMENTAL
Intervention: Other isotypes in SMS patients
Number of subjects: 31
Study 10892762 — intervention group
Group type: COMPARATOR
Intervention: Other isotypes in T1DM patients
Number of subjects: 31
Study 8751522 — intervention group
Group type: COMPARATOR
Intervention: High-dose aprotinin
Number of subjects: 115
Study 8751522 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aprotinin
Number of subjects: 115
Study 8751522 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 115
Study 1396839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (mean necessary effective patch dose: 125 cm2)
Number of subjects: 8
Study 1396839 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) capsules (administered q5h)
Number of subjects: 8
Study 1396839 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches and capsules
Number of subjects: 8
Study 30561539 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine (30 or 100 µg formulated in CAF01 or 100 µg formulated in Alhydrogel)
Number of subjects: 50
Study 30561539 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Verorab)
Number of subjects: 50
Study 30561539 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2-Alhydrogel (100 µg)
Number of subjects: 50
Study 30561539 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg GMZ2-CAF01
Number of subjects: 50
Study 30561539 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2-CAF01
Number of subjects: 50
Study 30561539 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (GMZ2 and control)
Number of subjects: 50
Study 30561539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vaccine-specific antibody concentrations
Number of subjects: 50
Study 28892513 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (told that the odorant increases creativity)
Number of subjects: 90
Study 28892513 — intervention group
Group type: COMPARATOR
Intervention: Control group (smelled and rated an odorant)
Number of subjects: 90
Study 25763862 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg and 100 mg
Number of subjects: 0
Study 25763862 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 0
Study 25763862 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 25763862 — intervention group
Group type: COMPARATOR
Intervention: Golimumab
Number of subjects: 0
Study 25763862 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 23571117 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (real-time feedback)
Number of subjects: 69
Study 23571117 — intervention group
Group type: COMPARATOR
Intervention: No-feedback group
Number of subjects: 69
Study 21717876 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy with Polidocanol
Number of subjects: 50
Study 21717876 — intervention group
Group type: COMPARATOR
Intervention: Liquid sclerotherapy with Polidocanol
Number of subjects: 50
Study 20858034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel combined with ketamine (100 mg)
Number of subjects: 60
Study 20858034 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine gel combined with normal saline
Number of subjects: 60
Study 17472414 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (100mg bid)
Number of subjects: 111
Study 17472414 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (400mg qd)
Number of subjects: 111
Study 17472414 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (400mg bid)
Number of subjects: 111
Study 17472414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 15053030 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cognitive-behavioral group intervention
Number of subjects: 235
Study 15053030 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy on request (comparison condition)
Number of subjects: 235
Study 12195844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised fluticasone propionate (FP) 2 x 0.5 mg/2 ml bd
Number of subjects: 31
Study 12195844 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone 2 mg/kg/day for 4 days followed by 1 mg/kg/day for 3 days (maximum 40 mg then 20 mg)
Number of subjects: 31
Study 9696374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal mafosfamide at a dose of 20 mg once or twice weekly until remission, followed by weekly administrations for consolidation and every 3 to 4 weeks for maintenance
Number of subjects: 16
Study 8596759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) 10 or 20 mg
Number of subjects: 44
Study 8596759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2520814 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg, twice daily)
Number of subjects: 57
Study 2520814 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen-sodium (500 mg, twice daily)
Number of subjects: 57
Study 2520814 — intervention group
Group type: COMPARATOR
Intervention: Both flurbiprofen and naproxen-sodium
Number of subjects: 57
Study 1155823 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16
Study 1155823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16
Study 1155823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Ephedrine
Number of subjects: 16
Study 30786072 — intervention group
Group type: EXPERIMENTAL
Intervention: NC40 +PHY
Number of subjects: 504
Study 30786072 — intervention group
Group type: EXPERIMENTAL
Intervention: NC65 +PHY+CA
Number of subjects: 504
Study 30786072 — intervention group
Group type: COMPARATOR
Intervention: NC40
Number of subjects: 504
Study 30786072 — intervention group
Group type: COMPARATOR
Intervention: NC65
Number of subjects: 504
Study 30786072 — intervention group
Group type: COMPARATOR
Intervention: NC40 and NC65
Number of subjects: 504
Study 28132704 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-only
Number of subjects: 240
Study 28132704 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+HC
Number of subjects: 240
Study 28132704 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240